We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
AZ pays $100mm up front for rights to Rigel's RA candidate; rights later returned
08 Dec 2015
Executive Summary
AstraZeneca PLC will pay $100mm up front for exclusive worldwide development, manufacturing, and commercialization rights to Rigel's (small molecules for inflammation, autoimmune diseases, and metabolic conditions) fostamatinib (R788), a spleen tyrosine kinase (Syk) inhibitor that has completed Phase II trials for rheumatoid arthritis in patients who have not responded to prior drug therapies.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Terminated
Deal Type
Alliance
Includes Royalty or Profit Split Information
R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?